BioCryst Pharmaceuticals BCRX Stock options excluded as their inclusion would be anti-dilutive (in shares)
Stock options excluded as their inclusion would be anti-dilutive (in shares) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares)?
- BioCryst Pharmaceuticals (BCRX) reported stock options excluded as their inclusion would be anti-dilutive (in shares) of 50.8M in Q1 2026.
- How has BioCryst Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares) changed year-over-year?
- BioCryst Pharmaceuticals's stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 58.9% year-over-year, from 32M to 50.8M.
- What does stock options excluded as their inclusion would be anti-dilutive (in shares) mean?
- Tracks the number of stock options or other convertible securities that are excluded from diluted earnings per share calculations because their exercise price exceeds the current market price. These instruments are currently out-of-the-money and do not negatively impact reported earnings per share, but represent potential future dilution.